NATCO Pharma Ltd reported a 37.75 per cent decline in consolidated web revenue to ₹132.4 crore for Q3 FY2025, down from ₹212.7 crore in the identical quarter final 12 months. The corporate’s shares plummeted 17.28 per cent to ₹1,008.25 on the NSE, touching a 52-week low of ₹829.60.
The pharmaceutical firm’s consolidated income from operations fell 37.4 per cent to ₹474.8 crore, in comparison with ₹758.6 crore in Q3 FY2024. EBITDA witnessed a pointy decline of 85.5 per cent to ₹38.8 crore, with margins contracting by 2,717 foundation factors to eight.2 per cent.
- Learn additionally: Jubilant FoodWorks Q3 web ₹43.2 crore, income surges 56%
The earnings downturn was primarily attributed to weak formulation exports, which decreased to ₹285.8 crore from ₹605.6 crore year-over-year. Home formulation gross sales additionally dipped to ₹96.1 crore from ₹99.4 crore within the corresponding interval.
Regardless of decreased complete bills at ₹487.4 crore in comparison with ₹539.3 crore final 12 months, the corporate’s efficiency remained underneath stress as a result of weak income era.
Individually, the board declared a 3rd interim dividend of ₹1.50 per fairness share for FY2024-25, with February 18, 2025, set because the file date. The dividend fee is scheduled to begin from February 28, 2025.
